AxoGen (AXGN)
(Delayed Data from NSDQ)
$9.18 USD
+0.52 (6.00%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $9.17 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.18 USD
+0.52 (6.00%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $9.17 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
by Zacks Equity Research
Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
4 Must-Buy Stocks for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights AxoGen, Western Digital and Gen Digital
by Zacks Equity Research
AxoGen, Western Digital and Gen Digital have been highlighted in this Screen of The Week article.
3 Best Stocks to Buy for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.
Here's Why Momentum in AxoGen (AXGN) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group
by Zacks Equity Research
AxoGen, Western Digital, Accolade and Credo Technology Group are part of the Screen of the Week article.
4 Top Stocks That Flaunt Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group
by Zacks Equity Research
Aspen Aerogels, AxoGen and Credo Technology Group are part of the Zacks Screen of the Week article.
3 Stocks Worth a Look for Solid Earnings Acceleration
by Tirthankar Chakraborty
Keep a tab on stocks such as Aspen Aerogels (ASPN), AxoGen (AXGN) and Credo Technology Group (CRDO) for superb earnings acceleration.
Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Dynatronics Corporation (DYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?